Premium
Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature
Author(s) -
Sorge Caryn,
Li Rong,
Singh Sumit,
Reddy Alyssa T.,
Solomon David A.,
Perry Arie,
Friedman Gregory K.
Publication year - 2017
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.26708
Subject(s) - medicine , temozolomide , isocitrate dehydrogenase , lomustine , oligodendroglioma , atrx , radiation therapy , oncology , chemotherapy , glioma , mutation , astrocytoma , vincristine , cancer research , biochemistry , chemistry , cyclophosphamide , gene , enzyme
Anaplastic oligodendroglioma (AO) is rare in children. Treatment typically consists of varying combinations of surgery, chemotherapy, and radiotherapy. We present a pediatric case of frontal lobe AO with periventricular subcallosal extension and local leptomeningeal involvement. The isocitrate dehydrogenase (IDH) wild‐type tumor was MGMT methylated and contained an ATRX mutation, BRAF alteration, and 1p/19q co‐deletion; a combination of alterations mostly encountered in pediatric oligodendrogliomas. The patient underwent a near total resection and had a complete, durable response to temozolomide alone, suggesting that conservative management without radiation may be appropriate in some cases. We review the literature of this uncommon subtype of glioma in children.